Long‐term use of metformin and colorectal cancer risk in type II diabetics: a population‐based case–control study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC). Epidemiological studies, however, have been equivocal. We undertook this study to assess whether metformin prevents CRC in individuals with type II diabetes. We performed a nested case–control study restricted to Danish citizens with type II diabetes. Data were collected from four Danish nationwide registries. Cases were type II diabetics with a primary CRC between 2000 and 2009, and controls were sampled among subjects with type II diabetes. Long‐term exposure to metformin was defined by the redeeming of prescriptions for a cumulative dose of 2000 g within 5 years prior to the index date. To control for potential confounders, we used unconditional logistic regression. We generated adjusted odds ratios (OR) for the association between metformin and CRC and performed subanalyses for selected subgroups and for the dose–response relation. We identified 2088 cases and 9060 controls during the study period. The association between long‐term metformin use and CRC gave an adjusted OR at 0.83 (95% CI 0.68–1.00). A protective effect on CRC with long‐term use of metformin was only evident for women (OR 0.66 vs. 0.99 for men). There was a significant dose–response association of metformin use >250 defined daily dose (DDD) and for the duration of metformin use >1 year. We found an indication of a protective effect of long‐term metformin use against CRC in type II diabetics, although this effect was only seen in women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968 · cited 5×
“The latter was made by using NPR which is another strength of the study.”
BackgroundInfluentialAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“Furthermore, several other studies have reported a moderate gender difference in the metformin–cancer association, without commenting on it [30, 31].”
BackgroundDiabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038 · cited 1×
“There is an association between type II diabetes and cancer development, and both diseases share many of the same sociodemographic and life style risks, for example, age, gender, BMI, physical activity that play a critical role in the progression of the two diseases [37, 38].”
BackgroundNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“Furthermore, several other studies have reported a moderate gender difference in the metformin–cancer association, without commenting on it [30, 31].”
BackgroundMetformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 2×
“Several experimental studies have shown that metformin is likely to have anticancerous effects in both in vivo and in vitro settings [3–5].”
BackgroundInoue, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1871 · Cited by 561
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 1×
“Metformin is a widely used antidiabetic agent with over 120 million users worldwide in 2010 [1].”
BackgroundTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Cited by
Liu, F., Yan, L., Wang, Z., Lu, Y., Chu, Y., Li, X., Liu, Y., Rui, D., Nie, S., & Xiang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.13762 · Cited by 99
“Majken Cardel [14] 2014 case– control Danish 20002009 164 1255 842 5454 0.”
ResultHe, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59
Risk Factors for Colorectal Cancer
Y Peterson, C. (2015) · MOJ Surgery · doi:10.15406/mojs.2015.02.00015 · Cited by 6
Metadata
- Authors
- Cardel, M., Jensen, S. M., Pottegård, A., Jørgensen, T. L., & Hallas, J.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2014-08-05
- Volume
- 3
- Issue
- 5
- Pages
- 1458-1466
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2066448350
- Cited by
- 46
- References
- 13
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.